مزوتلین
برای مطالعهٔ بیشتر

Alvarez H, Rojas PL, Yong KT, Ding H, Xu G, Prasad PN,  et al. (December 2008). "Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy". Nanomedicine. 4 (4): 295–301. doi:10.1016/j.nano.2008.06.006. PMC 2606904. PMID 18691948.
Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G,  et al. (April 2010). "Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein". Occupational and Environmental Medicine. 67 (4): 233–236. doi:10.1136/oem.2009.049205. PMID 19858537. S2CID 207017988.
Pu RT, Pang Y, Michael CW (January 2008). "Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions". Diagnostic Cytopathology. 36 (1): 20–25. doi:10.1002/dc.20747. hdl:2027.42/57547. PMID 18064689. S2CID 10096707.
Inami K, Kajino K, Abe M, Hagiwara Y, Maeda M, Suyama M,  et al. (December 2008). "Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma". Oncology Reports. 20 (6): 1375–1380. doi:10.3892/or_00000155. PMID 19020717.
Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P,  et al. (August 2008). "Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study". Lung Cancer. 61 (2): 235–243. doi:10.1016/j.lungcan.2007.12.025. PMID 18281122.
Johnson MD, Vito F, O'Connell MJ (June 2008). "Mesothelin expression in the leptomeninges and meningiomas". The Journal of Histochemistry and Cytochemistry. 56 (6): 579–585. doi:10.1369/jhc.2008.950477. PMC 2386771. PMID 18347077.
Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T (November 2008). "Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer". Journal of Thoracic Oncology. 3 (11): 1317–1324. doi:10.1097/JTO.0b013e318187491c. PMID 18978568. S2CID 5183602.
Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M,  et al. (January 2008). "Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions". The Annals of Thoracic Surgery. 85 (1): 265–72, discussion 272. doi:10.1016/j.athoracsur.2007.07.042. PMID 18154821.
Sapede C, Gauvrit A, Barbieux I, Padieu M, Cellerin L, Sagan C,  et al. (March 2008). "Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells". Cancer Science. 99 (3): 590–594. doi:10.1111/j.1349-7006.2007.00715.x. PMID 18167128. S2CID 205233632.
Li M, Bharadwaj U, Zhang R, Zhang S, Mu H, Fisher WE,  et al. (February 2008). "Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer". Molecular Cancer Therapeutics. 7 (2): 286–296. doi:10.1158/1535-7163.MCT-07-0483. PMC 2929838. PMID 18281514.
Uehara N, Matsuoka Y, Tsubura A (February 2008). "Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells". Molecular Cancer Research. 6 (2): 186–193. doi:10.1158/1541-7786.MCR-07-0254. PMID 18245228.
Iwahori K, Osaki T, Serada S, Fujimoto M, Suzuki H, Kishi Y,  et al. (October 2008). "Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin". Lung Cancer. 62 (1): 45–54. doi:10.1016/j.lungcan.2008.02.012. PMID 18394747.
Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW (August 2008). "Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma". Journal of Thoracic Oncology. 3 (8): 851–857. doi:10.1097/JTO.0b013e318180477b. PMID 18670302. S2CID 12405738.
Shiomi K, Hagiwara Y, Sonoue K, Segawa T, Miyashita K, Maeda M,  et al. (March 2008). "Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma". Clinical Cancer Research. 14 (5): 1431–1437. doi:10.1158/1078-0432.CCR-07-1613. PMID 18316566.
Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, Lee B, Ho M (February 2009). "A binding domain on mesothelin for CA125/MUC16". The Journal of Biological Chemistry. 284 (6): 3739–3749. doi:10.1074/jbc.M806776200. PMC 2635045. PMID 19075018.
Chang MC, Chen CA, Hsieh CY, Lee CN, Su YN, Hu YH, Cheng WF (December 2009). "Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway". The Biochemical Journal. 424 (3): 449–458. doi:10.1042/BJ20082196. PMID 19747165.
Cheng WF, Huang CY, Chang MC, Hu YH, Chiang YC, Chen YL,  et al. (April 2009). "High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma". British Journal of Cancer. 100 (7): 1144–1153. doi:10.1038/sj.bjc.6604964. PMC 2669998. PMID 19293794.
Hellstrom I, Hellstrom KE (2008). "SMRP and HE4 as Biomarkers for Ovarian Carcinoma when Used Alone and in Combination with CA125 and/Or Each Other". Ovarian Cancer. Advances in Experimental Medicine and Biology. Vol. 622. pp. 15–21. doi:10.1007/978-0-387-68969-2_2. ISBN 978-0-387-68966-1. PMID 18546615.
Bharadwaj U, Li M, Chen C, Yao Q (November 2008). "Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3". Molecular Cancer Research. 6 (11): 1755–1765. doi:10.1158/1541-7786.MCR-08-0095. PMC 2929833. PMID 19010822.